Effect of Dapagriflozin on renal dysfunction in patients with heart failure

Effect of Dapagriflozin on renal dysfunction in patients with heart failure - Effect of Dapagriflozin on renal dysfunction in patients with heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044902

Enrollment

100

Registered

2021-07-19

Start date

2021-01-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic heart failure patients with reduced left ventricular systolic function (EF<50%), no history of heart failure hospitalization within 180 days

Exclusion criteria

Exclusion criteria: Contraindications in the attached text

Design outcomes

Primary

Measure	Time frame
Comparison of changes in renal function and renal damage markers at the admission of dapagriflozin, at 2 weeks, and at 2 month	—

Secondary

Measure	Time frame
Relationship between renal function and renal damage markers and 1-year composite endpoint (eGFR decline, end-stage renal failure, heart failure hospitalization, and death) Changes in QTc dispersion	—

Countries

Japan

Contacts

Public ContactYu Horiuchi

Mitsui Memorial Hospital Cardiology

yooouyou@gmail.com03-3862-9111

Outcome results